Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mhb Labs Inc. currently manages a patent portfolio focused on Biotechnology & Pharmaceuticals. The prosecution activity is highly concentrated, with 1 pending office action currently assigned to a single examiner, WAX, ROBERT A. This examiner is also the busiest examiner for the company, handling 1 pending action. The lack of diversity in the examiner pool suggests that the company's immediate patenting success is tied to a single individual's perspective.
The portfolio shows a very narrow distribution across the USPTO, as evidenced by the 1 distinct examiner and 1 distinct art unit involved in current proceedings. For a practitioner, this indicates that the outcome of the 1 pending office action will be determined by a single individual's interpretation of the Biotechnology & Pharmaceuticals technology area. The concentration in 1 distinct art unit suggests a highly specialized set of claims that do not cross into other technical disciplines. This centralized prosecution environment allows for a focused strategy but also increases the impact of the 1 distinct examiner's specific preferences and past decisions on the company's intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17281902 | EXTENDED RELEASE FORMULATIONS OF HUMAN CHORIONIC GONADOTROPIN (HCG) | WAX, ROBERT A | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17281902 | EXTENDED RELEASE FORMULATIONS OF HUMAN CHORIONIC GONADOTROPIN (HCG) | WAX, ROBERT A | 1615 | §102§103Other | Non-Final OA | — | Pending | Mar 31, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMhb Labs Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert A Wax has the most, with 1 of Mhb Labs Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
